Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 10/20 | 0.73 |
| ▸ | ULK1 | O75385 | 3/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31592256 | 0.78 | IGF1R (0.85) | IGF1RMAPK10EGFR | |
| SCHEMBL13810320 | 0.77 | ULK1 (0.60) | IGF1RULK1MAPK8MAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL3811803 | 0.77 | ULK1 (0.59) | IGF1RULK1MAPK8MAPK9MAPK10 | |
| SCHEMBL6313704 | 0.76 | IGF1R (0.59) | IGF1RPIK3CA | |
| SCHEMBL31592567 | 0.75 | IGF1R (0.82) | IGF1REGFRBRD4 | |
| SCHEMBL31592371 | 0.74 | IGF1R (0.80) | IGF1RMAPK8MAPK9MAPK10EGFR | |
| SCHEMBL31592286 | 0.74 | IGF1R (0.79) | IGF1REGFRPIK3CA | |
| SCHEMBL11340289 | 0.72 | IGF1R (1.00) | IGF1RBRD4PKMYT1 | |
| SCHEMBL29576376 | 0.72 | WEE1 (0.60) | IGF1REGFRBRD4PKMYT1ALK | |
| SCHEMBL31592426 | 0.72 | IGF1R (0.76) | IGF1RMAPK8MAPK9MAPK10EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | IGF1R 1/4885ULK1 462/4885MAPK8 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.